This work builds on previous studies are administered by Tuszynski and others, demonstrating the therapeutic effects of nerve growth factor for patients with Alzheimer’s disease http://levitra-20.com here . In 2001, conducted Tuszynski and his team at UC San Diego Medical Center , the first surgical implants of NGF genes in the brains of Alzheimer patients with follow-up results show that patients a possible slowing of cognitive decline and increased metabolic function in the brain. NGF studies continue today, with Phase 2, multi – center studies in progress.
The protective and restorative effects of BDNF occurred independently of the formation of amyloid, a protein in the brain to form plaques in Alzheimer disease accumulate Many current experimental treatments for Alzheimer’s disease target amyloid production. So the potential role of BDNF as an alternative protective intervention is great potential interest, said Tuszynski. Because BDNF targets a different set of disease mechanisms than amyloid modulation, there is also potential for BDNF and amyloid-based treatments to combine theory, offers a two-pronged attack on the disease.
The marked delay between the time of the fatalities and when the data is has been collected.
Forward-Looking StatementsThis press release contains ‘forward-looking statements ‘within the meaning of the U.S. Private Securities Litigation reform Act of 1995 dictionary in like, but not limited, ‘look to the future ‘. ‘believe,”expect,”anticipate,”estimate,”intend,”plan,”targets,”likely,”will, ‘would ‘,’was ‘and’could ‘and similar expressions and Keyword identify forward-looking statements. Such forward-looking statements are based upon the current expectations to risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be taken as a representation by Amicus that the company goals be reach. Ineffective and of forward-looking statements in this release to be wrong. They can by inaccurate assumptions Amicus could do by known or unknown by known or unknown risks and uncertainties. For example, with a view to statements on the objectives, progress made and dates and results of ongoing discussions with the regulatory authorities and potential aims, progress, schedules and results of which clinical trials can be figures to differ considerably results to differ materially these press releases in this due to which risk and uncertainties in the economy by Amicus, including, without limitation: possible that dates from a Phase 3 study style on Amigal insufficient , support approval, the potential the results of the clinical or preclinical studies have indicated that this product candidates are uncertain or ineffective, of our dependency on third parties in the implementation of our clinical trial. Furthermore, the results of earlier clinical research and studies do not predictive for future results. Among the statements subject to other risks in our financial Report on Form 10 – K for the year period ended 31 In December 2008 list, with our other public filings with the Securities and Exchange Commission. You be advised undue reliance on undue reliance on this forward-looking statements which speak only than of the date valid for placed. Every forward-looking statements in their entireties by in their entirety by this cautionary statement , and Amicus assumes no liability whatsoever to revise or update this release in order to reflects events or circumstances accordance with the date of this release.